NasdaqGS - Nasdaq Real Time Price USD
Viatris Inc. (VTRS)
As of 11:08 AM EDT. Market Open.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
15,239,200.00
15,426,900.00
16,262,700.00
17,886,300.00
11,946,000.00
--
Cost of Revenue
9,002,000.00
8,988,300.00
9,765,700.00
12,310,800.00
8,149,300.00
--
Gross Profit
6,237,200.00
6,438,600.00
6,497,000.00
5,575,500.00
3,796,700.00
--
Operating Expense
5,852,600.00
5,455,300.00
4,841,300.00
5,210,200.00
3,857,200.00
--
Operating Income
384,600.00
983,300.00
1,655,700.00
365,300.00
-60,500.00
--
Net Non Operating Interest Income Expense
-566,600.00
-573,100.00
-592,400.00
-636,200.00
-497,800.00
--
Other Income Expense
-458,000.00
-207,300.00
1,749,900.00
-393,500.00
-162,900.00
--
Pretax Income
-640,000.00
202,900.00
2,813,200.00
-664,400.00
-721,200.00
--
Tax Provision
6,500.00
148,200.00
734,600.00
604,700.00
-51,300.00
--
Net Income Common Stockholders
-646,500.00
54,700.00
2,078,600.00
-1,269,100.00
-669,900.00
--
Diluted NI Available to Com Stockholders
-646,500.00
54,700.00
2,078,600.00
-1,269,100.00
-669,900.00
--
Basic EPS
-0.54
0.05
1.71
-1.05
-1.11
--
Diluted EPS
-0.54
0.05
1.71
-1.05
-1.11
--
Basic Average Shares
1,196,450.00
1,200,300.00
1,212,100.00
1,208,800.00
601,200.00
--
Diluted Average Shares
1,201,150.00
1,206,900.00
1,217,400.00
1,208,800.00
601,200.00
--
Total Operating Income as Reported
-38,800.00
766,200.00
1,614,900.00
-34,000.00
-210,800.00
--
Total Expenses
14,854,600.00
14,443,600.00
14,607,000.00
17,521,000.00
12,006,500.00
--
Net Income from Continuing & Discontinued Operation
-646,500.00
54,700.00
2,078,600.00
-1,269,100.00
-669,900.00
--
Normalized Income
-312,014.00
226,209.00
2,108,751.20
-977,611.00
-530,271.30
--
Interest Expense
566,600.00
573,100.00
592,400.00
636,200.00
497,800.00
--
Net Interest Income
-566,600.00
-573,100.00
-592,400.00
-636,200.00
-497,800.00
--
EBIT
-73,400.00
776,000.00
3,405,600.00
-28,200.00
-223,400.00
--
EBITDA
2,727,700.00
3,516,500.00
6,433,200.00
4,478,300.00
1,992,700.00
--
Reconciled Cost of Revenue
9,002,000.00
8,988,300.00
9,765,700.00
12,310,800.00
8,149,300.00
--
Reconciled Depreciation
2,801,100.00
2,740,500.00
3,027,600.00
4,506,500.00
2,216,100.00
--
Net Income from Continuing Operation Net Minority Interest
-646,500.00
54,700.00
2,078,600.00
-1,269,100.00
-669,900.00
--
Total Unusual Items Excluding Goodwill
-423,400.00
-217,100.00
-40,800.00
-399,300.00
-150,300.00
--
Total Unusual Items
-423,400.00
-217,100.00
-40,800.00
-399,300.00
-150,300.00
--
Normalized EBITDA
3,151,100.00
3,733,600.00
6,474,000.00
4,877,600.00
2,143,000.00
--
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
--
Tax Effect of Unusual Items
-88,914.00
-45,591.00
-10,648.80
-107,811.00
-10,671.30
--
12/31/2019 - 3/17/1980
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
TEVA Teva Pharmaceutical Industries Limited
18.04
-0.77%
HLN Haleon plc
9.89
-0.90%
ZTS Zoetis Inc.
188.10
-0.71%
TAK Takeda Pharmaceutical Company Limited
14.08
-0.53%
ELAN Elanco Animal Health Incorporated
12.35
-2.18%
BHC Bausch Health Companies Inc.
8.11
-0.80%
PRGO Perrigo Company plc
25.95
+0.38%
TLRY Tilray Brands, Inc.
1.6100
+1.90%
CTLT Catalent, Inc.
60.13
-0.08%
ACB Aurora Cannabis Inc.
5.67
+2.95%